Covid19 Clinical Trial
Official title:
The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Verified date | December 2021 |
Source | National Bureau of Economic Research, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Facebook ads with physician-delivered videos were shown before the Thanksgiving and Christmas holidays and focused on staying safe during the COVID pandemic by limiting travel and mask-wearing.
Status | Completed |
Enrollment | 820 |
Est. completion date | February 11, 2021 |
Est. primary completion date | February 11, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Individuals viewing the ads must be Facebook users, 18 years and older. Facebook will decide specifically which users receive the messages within a target geographical area (zip or county). Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
United States | JPAL North America | Cambridge | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
National Bureau of Economic Research, Inc. | Harvard University, Massachusetts General Hospital, Massachusetts Institute of Technology, Stanford University, Yale University |
United States,
Breza E, Stanford FC, Alsan M, Alsan B, Banerjee A, Chandrasekhar AG, Eichmeyer S, Glushko T, Goldsmith-Pinkham P, Holland K, Hoppe E, Karnani M, Liegl S, Loisel T, Ogbu-Nwobodo L, Olken BA, Torres C, Vautrey PL, Warner ET, Wootton S, Duflo E. Effects of — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Facebook Movement Metric | The change in movement metric is the percent change in distance covered in a day compared to the same day of the week in the benchmark period of February 2-29, 2020, by people who started the day in a particular location. We define holiday travel as travel during the three days preceding each holiday, since the available data does not allow us to compute the impact of the intervention on the return travel (after the holiday). The reason is that the mobility data describes the behavior throughout the day, for people who were in each county that morning. Since the campaign was targeted based on home location, we can only capture its impact on travel away from home, not back home. | November 26, 2020 (Thanksgiving); December 24-25, 2020 (Christmas); February 2-29, 2020 (Baseline benchmark) | |
Primary | Percentage Leaving Home on Day of Holiday | The Facebook stay put metric is the percentage of people who stay within a small geographical area (a "tile" of 600m*600m in which they started the day). We use it to compute the share of people leaving home on the day of the holiday (i.e. this variable = 1 - stay put on the day of the holiday). | November 26, 2020 (Thanksgiving); December 24-25, 2020 (Christmas) | |
Primary | Inverse Hyperbolic Sine of COVID-19 Cases | Inverse hyperbolic sine of COVID-19 cases during a 14 day period starting 5 days after each holiday | December 1-14 (Thanksgiving arms) and January 1-14 (Christmas arms) | |
Secondary | Knowledge of COVID-19 Prevention Message (Recall of ad, Intent to Travel, Mask Wearing and Beliefs About Travel) | Facebook will ask a set of users in treated zip codes to answer four survey questions (each user answers only one question each). A small within-zip control group will be held from being treated, enabling comparisons between those who see the videos and those who don't. These questions will be asked a few days after the ad is shown on the User's feed and will include 1) recall of the ad; 2) intention of traveling over holiday; 3) intention of wearing a mask; and 4) beliefs about whether people should travel over holiday. | up to one month | |
Secondary | Average Number of Tiles People Occupy (Mobility Measure) | this measures each day "how much people move around by counting the number of level-16 Bing tiles they are seen in within a day. People seen in more tiles are probably moving around more, while people seen in fewer are probably moving around less. Each day take eligible people in a given region and compute the number of distinct tiles they were seen in." This is aggregated to the county level. | up to one month | |
Secondary | Percentage of Eligible Participants Only Observed in a Single Level-16 Bing Tile (no Change in Movement) | Facebook "Stay-put" data: this measures each day "the percentage of eligible people who are only observed in a single level-16 Bing tile (600m x 600m) during the course of a day" aggregated to they county level. | up to one month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |